J Clin Med . Immunologic Dysregulation and Hypercoagulability as a Pathophysiologic Background in COVID-19 Infection and the Immunomodulating Role of Colchicine

[tetano]

J Clin Med


. 2021 Oct 31;10(21):5128.
doi: 10.3390/jcm10215128.
Immunologic Dysregulation and Hypercoagulability as a Pathophysiologic Background in COVID-19 Infection and the Immunomodulating Role of Colchicine


Dimitrios A Vrachatis ¹ , Konstantinos A Papathanasiou ¹ , Sotiria G Giotaki ¹ , Konstantinos Raisakis ² , Charalampos Kossyvakis ² , Andreas Kaoukis ² , Fotis Kolokathis ¹ , Gerasimos Deftereos ² , Konstantinos E Iliodromitis ^{3 4} , Dimitrios Avramides ² , Harilaos Bogossian ^{3 4} , Gerasimos Siasos ¹ , George Giannopoulos ⁵ , Bernhard Reimers ⁶ , Alexandra Lansky ⁷ , Jean-Claude Tardif ⁸ , Spyridon Deftereos ¹



Affiliations

• PMID: 34768648
• DOI: 10.3390/jcm10215128

Abstract

In 2020, SARS-COV-2 put health systems under unprecedented resource and manpower pressure leading to significant number of deaths. Expectedly, researchers sought to shed light on the pathophysiologic background of this novel disease (COVID-19) as well as to facilitate the design of effective therapeutic modalities. Indeed, early enough the pivotal role of inflammatory and thrombotic pathways in SARS-COV-2 infection has been illustrated. The purpose of this article is to briefly present the epidemiologic and clinical features of COVID-19, analyze the pathophysiologic importance of immunologic dysregulation and hypercoagulability in developing disease complications and finally to present an up-to-date systematic review of colchicine's immunomodulating capacity in view of hindering coronavirus complications.

Keywords: COVID-19; cardioprotection; colchicine; cytokine release syndrome; hypercoagulability.